Evaluating potential treatments with state-of-the-art neuroinflammation models.
The first ever recorded description of a neuroinflammatory disorder goes as far back as the 1200s. Defined as the result of chronic inflammation in the Central Nervous System (CNS), neuroinflammation can be caused by both chronic events in the form of neurodegenerative disorders (Alzheimer’s, Prakinson’s and Huntington’s diseases) and acute events like viral infections and traumatic brain injuries.
The costs from neurodegenerative diseases are north of $655 billion per year in medical expenses and economic losses.
While novel therapies are emerging every day, most early clinical trials have fallen short of achieving satisfactory therapeutic effect. This only drives us forward at PharmaLegacy to support you in your preclinical trials, providing you with all the rigorous data you need for your neuroinflammation pipelines.
MODELS / SERVICES
EAE Model: MBP-induced EAE in Lewis Rats
Case Study: PLP-Induced Relapsing-remitting EAE in SJL/J Mice
The capability to succeed:
- 1000+ validated animal models of disease spanning 40+ diseases
- 380,000 square feet of facility space
- Capacity to house over 30,000 rodents and large animals
- On-site capacity for up to 350 non-human primates, with off-site capacity for up to 30,000 Cynomolgus and Rhesus monkeys
Never lower your standards when choosing a CRO. Work with PharmaLegacy.
Can you trust your animal model to provide you with the correct answers?
No animal study can predict with complete certainty how a therapy will perform in human subjects, but it is PharmaLegacy’s job to ensure that you come as close to certainty as possible. Download our brochure on non-human primate (NHP) models and see how PharmaLegacy ensures that your studies utilize the most physiologically relevant models.